2019 Prize Winners



ACP McElwain Prize

Dr Kroopa Joshi


AstraZeneca Young Scientist Poster Prize

A CRISPR/Cas9-mediated Screening of the F-box domain-containing E3 Ligase family in Intestinal Organoids

Hossein Kashfi, Cancer Genetic and Stem cell group, Division of cancer and stem cell, Nottingham University


British Association of Cancer Research (BACR) – AstraZeneca Young Scientist Frank Rose Award

3-D cell culture models for detection of biomarker indicating anti-EGFR antibody resistance in colon cancer patients

Nicola Valeri, The Institute for Cancer Research


British Association of Cancer Research (BACR) – Astex Pharmaceuticals Roger Griffin Prize for Cancer Drug Discovery

Liam Hudson, Global Discovery Chemistry, USA


British Association of Cancer Research (BACR) Chris Marshall Prize for Cell Signalling

Georgouli Mirella, King’s College London, UK


British Association of Cancer Research (BACR) Gordon Hamilton-Fairley Young Investigator Award 


Children’s Cancer and Leukaemia Group (CCLG) Award

A high-throughput sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

Eleanor WattUCL, London UK

CREST Awards


National Cancer Research Institute (NCRI) Bursary Prizes

The placebo response in trials of drug treatments for cancer-related fatigue: A systematic review, meta-analysis and meta-regression

Maria del Rocio Roji Buqueras, University College London, London, UK

Meat intake and cancer risk: prospective analyses in UK Biobank

Anika Knuppel, Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK

The p53/p21 axis suppresses 5FU-induced, ATM/ATR-STAT3-mediated activation of PD-L1 

Tamas Sessler, Centre for Cancer Research & Cell Biology Queen’s University Belfast, Belfast, UK

Investigating COX isoform dependency in intestinal tumourigenesis 

Noha-Ehssan Mohamed, Cancer Research UK Beatson Institute, Glasgow, UK
Camille Maringe, London School of Hygienen and Tropical Medicine, London, UK

National Cancer Research Institute (NCRI) Future of Research Bursaries 

A potent synergy between FOXG1 overexpression and Wnt signaling drives cell cycle re-entry in quiescent glioblastoma stem cells 

Faye Robertson, University of Edinburgh, Edinburgh, UK

Garth Funston, Department of Public Health and Primary Care, University of Cambridge, UK

Role of cholesterol in colon cancer and its impact on AOM/DSS induced mouse intestinal tumourigenesis

Shyamananda Singh Mayengbam ,Manoj Kumar Bhat, National Centre for Cell Science, Savitribai Phule Pune University, Pune, India

National Cancer Research Institute (NCRI) Werth Trust Award

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)

Peter Forsyth, Moffitt Cancer Center and Research Institute, Tampa, US

Royal College of Radiologists (RCR) Ross Award Prize

Predicting risk of early relapse with circulating tumour DNA for advanced ER+ breast cancer patients in the PALOMA-3 trial 

Ben O’Leary, The Institute of Cancer Research


On-site challenges prizes


Below you can find a list of prizes that can be won by enjoying your time at the Conference.

Participate daily in the Passport Completion and our Step Challenge for a chance to win.




Gifted by: Prize:
British Association for Cancer Research I-Tunes Voucher
Cancer Clinical Trials Unit Scotland (CaCTUS) Scottish Hamper
Macmillan Cancer Support Amazon Voucher
Marie Curie Silver Pen Giveaway
PCR Biosystems Love2shop gift voucher
Zizzi Glasgow Dine on the 3-course set menu with bottle of house wine for 2
The Corinthian Afternoon tea with a bottle of prosecco in brasserie for 2
Rabbie’s 1-day tour of choice in Glasgow, Edinburgh or Aberdeen for 2
Glasgow Convention Bureau 2 Glasgow City Sightseeing vouchers
SEC Glasgow Voucher (TBA)
Miltenyi Biotec Amazon Echo Dot
Promega UK Amazon Echo Dot
Bionano Genomics £50 gift voucher


Interactive and practical sessions and case studies

NCRI Conference 2019 – Bursaries for Patients & Carers (external)

Please use the following form to apply for a consumer bursary to attend the NCRI Conference 2019.
This may include involvement with charitable organisations or research funders for example; as well as describing any links you may have to patient groups e.g. a local support group

Important Information

If your application is successful, you will be emailed with instructions on how to register online, which will also enable you to select which sessions you wish to attend. Prior to the Conference, you will also be sent a 'Bursary Holders Information Pack' containing further key information.

Please ensure you have read through the terms and conditions thoroughly (see below). If you have any enquiries in regards to the bursary scheme please contact the NCRI Research Involvement Officer or call 0203 469 6121.

Terms and conditions

Full or partial bursaries may be awarded which include Conference registration, accommodation, complementary refreshments offered at the Conference, Consumer Bursary Holders’ Welcome Buffet and Conference social event. Attendance to the Welcome Buffet and Conference social event is expected, as part of the Conference Bursary. Given this, alternative dining arrangements during these events will not be reimbursed.

No honoraria or attendance fees apply and travel expenses within the UK will be reimbursed according to the NCRI Conference Travel expenses policy. Please note that this is NOT the same as the NCRI Expenses Policy.

For budget tracking purposes all travel must be booked and costs incurred confirmed to the NCRI Research Involvement Officer as soon as possible, but no later than Friday 6th September 2019.


All hotel accommodation will be booked by the NCRI Conference and Events Team according to the information provided on your conference registration form, which needs to be completed after confirmation of your bursary application and will be within easy reach of the Conference venue. The bursary does not cover hotels booked independently. Accommodation is provided on a bed and breakfast basis and bursary holders will be liable for any ‘extras’ (e.g. telephone calls, room service, etc). Accommodation is based on single occupancy and is fully funded for bursary holders only. If the bursary holder travels with a carer the carer’s accommodation might need to be funded separately.

Amendments/cancellations to your accommodation booking must be made no later than Friday 6th September 2019.

please contact conference@ncri.org.uk in this instance. Any amendments/cancellations after this will incur a charge to the bursary holder, unless in the case of extenuating circumstances, which can be discussed with the Head of Clinical Research Groups.

Conference registration:

Registration includes attendance at all sessions on the specified day(s). Lunch is provided on Monday and Tuesday. Beverages will also be available during refreshment breaks. Bursaries will also include the Conference social event on Monday evening.

Feedback survey:

Completion of the feedback surveys after the Conference is mandatory and it is important for the development of our processes and future Conferences. Questions related to the bursary scheme are embedded within the electronic feedback survey. It is mandated to complete and submit the form as soon as possible after your attendance at the Conference and prior to you submitting any expenses claim. Expenses claims will be approved only after the questionnaire has been completed. Bursary Holders are also required to complete feedback survey forms for specific consumer activities and events.

Claiming your expenses:

All claims must be made using the relevant form (via the NCRI Research Involvement Officer) within two months of the last day of the Conference (i.e. by Sunday 5th January 2019). Late claims will not be reimbursed. Please allow 30 days for payment of your expenses.

The NCRI will not pass on your details to any outside organisation without your prior written permission, however, your name and affiliation will appear in the delegate list in the consumer pack and participants list.


THE cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Monday).

Researchers led by Professor Chris Twelves, based at the University of Leeds and Leeds Teaching Hospitals NHS Trust, looked at two major clinical trials of more than 1,800 women with breast cancer that had started to spread to other parts of the body. The phase III trials – the final stage of testing before deciding whether a drug can be prescribed to patients – compared the survival of women treated with eribulin* to those given standard treatment.

The two studies showed an overall improvement in survival of more than two months for women treated with eribulin**. The most significant improvement was seen in women with the advanced triple negative form of breast cancer, where there are limited treatment options; these women’s survival improved by nearly five months. There was also a survival boost of more than two months for women with the HER2 negative form of breast cancer***.

Cancer spreading to other organs – called metastasis – is responsible for around 90 per cent of all cancer deaths. And, when patients with breast cancer are diagnosed after the disease has started to spread, 10-year survival is around one in 10, compared to nearly nine in 10 for those diagnosed at the earliest stage.

Study author, Professor Chris Twelves, said: “Our results show a substantial improvement in survival for women with metastatic triple negative breast cancer, and a more modest, but significant, benefit for those with HER2 negative breast cancers.

“Eribulin has previously been offered to women who’ve already been through several lines of chemotherapy. But the European Union has recently approved eribulin for patients who have received less treatment for their breast cancer, which means we hope to give more patients another treatment option in the not-too-distant future.”

“Despite advances in the diagnosis and treatment of women with breast cancer, more than 11,600 women still die from invasive breast cancer each year in the UK. New and better treatments are needed for people fighting the disease.”

Eribulin works by stopping the cancer cells from separating into two new cells. It is a type of drug called a microtubule inhibitor. Eribulin was originally developed from a sea sponge called Halichondria okadai but is now made in the laboratory.

Martin Ledwick, head information nurse at Cancer Research UK, said: “These results are encouraging and may offer valuable extra time to patients whose cancers have stopped responding to conventional treatments and have few options left. Advanced breast cancer can be very difficult to treat so these results take us a small, important step in the right direction.

“Although eribulin isn’t a cure, it’s an extra treatment option for patients with advanced breast cancer, which can be priceless to them and their families.”


 For media enquiries please contact Greg Jones on 0151 707 4642/3/4/5
or, out-of-hours, the duty press officer on07050 264 059

Notes to Editors:

Read the full abstract – http://conference.ncri.org.uk/abstracts/2014/abstracts/A036.html

*Eribulin (also called eribulin mesylate or Halaven) is a chemotherapy drug used to treat advanced breast cancer. It is usually given to people who have already had at least two other courses of chemotherapy. Eribulin works by stopping (inhibiting) the cancer cells from separating into two new cells. It is a type of drug called a microtubule inhibitor.

** Overall survival for women treated with eribulin was 15.2 months, compared to 12.8 months for women given standard therapies. Women with HER+ breast cancer saw no statistically significant improvement.

*** HER2 stands for human epidermal growth factor receptor. It is a protein found in small amounts on some normal cells, including breast cells, stomach cells and bladder cells. It is one of the proteins involved in cell growth. Some cancers have cells with large amounts of this protein and they are called HER2 positive. These cancers can be treated with drugs that target the HER2 protein. If a cancer does not have large amounts of the HER2 protein it is called HER2 negative.

Triple negative breast cancers are cancers that don’t have receptors for oestrogen, progesterone or Her2. Only around 15 out of every 100 breast cancers (15%) are triple negative.

About the NCRI

  • The National Cancer Research Institute (NCRI) is a UK-wide partnership between the government, charity and industry. Its role is to promote cooperation in cancer research.
  • NCRI Partners are: the Association of the British Pharmaceutical Industry (ABPI); Biotechnology and Biological Sciences Research Council; Breakthrough Breast Cancer; Breast Cancer Campaign; Cancer Research UK; Children with Cancer UK; Department of Health; Economic and Social Research Council; Leukaemia & Lymphoma Research; Ludwig Institute for Cancer Research; Macmillan Cancer Support; Marie Curie Cancer Care; Medical Research Council; Northern Ireland Health and Social Care (Research & Development Office); Prostate Cancer UK; Roy Castle Lung Cancer Foundation; Scottish Government Health and Social Care Directorates (Chief Scientist Office); Tenovus; Welsh Government (National Institute for Social Care and Health Research); Worldwide Cancer Research (formerly the Association for International Cancer Research); Wellcome Trust; and Yorkshire Cancer Research.
  • For more information visit www.ncri.org.uk

About the NCRI Cancer Conference

  • The National Cancer Research Institute (NCRI) Cancer Conference is the UK’s major forum for showcasing the best British and international cancer research.
  • The Conference offers unique opportunities for networking and sharing knowledge by bringing together world-leading experts from all cancer research disciplines.
  • The tenth NCRI Cancer Conference is taking place from 2–5 November 2014 at the BT Convention Centre in Liverpool.
  • For more information visit conference.ncri.org.uk

About Cancer Research UK

  • Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
  • Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
  • Today, 2 in 4 people survive cancer. Cancer Research UK’s ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK’s vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK’s work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.